
Immunocore Holdings plc – NASDAQ:IMCR
Immunocore Holdings stock price today
Immunocore Holdings stock price monthly change
Immunocore Holdings stock price quarterly change
Immunocore Holdings stock price yearly change
Immunocore Holdings key metrics
Market Cap | 1.41B |
Enterprise value | 2.11B |
P/E | -44.31 |
EV/Sales | 14.68 |
EV/EBITDA | -66.55 |
Price/Sales | 12.05 |
Price/Book | 6.21 |
PEG ratio | -0.62 |
EPS | -1.28 |
Revenue | 275.38M |
EBITDA | -35.27M |
Income | -63.02M |
Revenue Q/Q | 58.28% |
Revenue Y/Y | 66.09% |
Profit margin | -28.68% |
Oper. margin | -27.56% |
Gross margin | 99.68% |
EBIT margin | -27.56% |
EBITDA margin | -12.81% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmunocore Holdings stock price history
Immunocore Holdings stock forecast
Immunocore Holdings financial statements
$70.2
Potential upside: 117.06%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 47.76M | -14.07M | -29.47% |
---|---|---|---|
Sep 2023 | 51.48M | 1.90M | 3.7% |
Dec 2023 | 105.63M | -26.41M | -25.01% |
Mar 2024 | 70.50M | -24.43M | -34.66% |
Jun 2023 | 440360000 | 163.08M | 37.03% |
---|---|---|---|
Sep 2023 | 464119000 | 172.57M | 37.18% |
Dec 2023 | 597001000 | 228.15M | 38.22% |
Mar 2024 | 993987000 | 634.45M | 63.83% |
Jun 2023 | -2.39M | 2.70M | 7.35M |
---|---|---|---|
Sep 2023 | 5.11M | 2.14M | 6.41M |
Dec 2023 | -8.57M | -9.87M | 18.08M |
Mar 2024 | -4.58M | -430K | 396.01M |
Immunocore Holdings alternative data
Aug 2023 | 408 |
---|---|
Sep 2023 | 408 |
Oct 2023 | 408 |
Nov 2023 | 408 |
Dec 2023 | 408 |
Jan 2024 | 408 |
Feb 2024 | 408 |
Mar 2024 | 497 |
Apr 2024 | 497 |
May 2024 | 497 |
Jun 2024 | 497 |
Jul 2024 | 497 |
Immunocore Holdings other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 4375 |
Feb 2024 | 0 | 120000 |
Apr 2024 | 0 | 4375 |
Quarter | Transcript |
---|---|
Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q4 2022 1 Mar 2023 | Q4 2022 Earnings Call Transcript |
Q2 2022 10 Aug 2022 | Q2 2022 Earnings Call Transcript |
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Immunocore: First Half Of 2024 IMC-F106C Data Expected
Immunocore: KIMMTRAK Adoption Continues At Rapid Pace, Expanding To New Markets, Reiterate Buy
August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February
August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge
April MDA Breakout Stocks/ETFs Week 16 - 2023: High-Frequency Gainers To Give You An Edge
Immunocore Holdings: A Meteoric Rise Likely Here To Stay
Immunocore: Potential To Unlock Capital With New Melanoma Treatment Paradigm
Immunocore: Attractive Commercial-Stage Biopharma
-
What's the price of Immunocore Holdings stock today?
One share of Immunocore Holdings stock can currently be purchased for approximately $32.34.
-
When is Immunocore Holdings's next earnings date?
Unfortunately, Immunocore Holdings's (IMCR) next earnings date is currently unknown.
-
Does Immunocore Holdings pay dividends?
No, Immunocore Holdings does not pay dividends.
-
How much money does Immunocore Holdings make?
Immunocore Holdings has a market capitalization of 1.41B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 73.53% to 249.43M US dollars.
-
What is Immunocore Holdings's stock symbol?
Immunocore Holdings plc is traded on the NASDAQ under the ticker symbol "IMCR".
-
What is Immunocore Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immunocore Holdings?
Shares of Immunocore Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Immunocore Holdings have?
As Jul 2024, Immunocore Holdings employs 497 workers.
-
When Immunocore Holdings went public?
Immunocore Holdings plc is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
-
What is Immunocore Holdings's official website?
The official website for Immunocore Holdings is immunocore.com.
-
How can i contact Immunocore Holdings?
Immunocore Holdings can be reached via phone at +44 1235 438600.
-
What is Immunocore Holdings stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Immunocore Holdings in the last 12 months, the avarage price target is $70.2. The average price target represents a 117.06% change from the last price of $32.34.
Immunocore Holdings company profile:

Immunocore Holdings plc
immunocore.comNASDAQ
497
Biotechnology
Healthcare
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Abingdon, OX14 4RY
CIK: 0001671927
ISIN: US45258D1054
CUSIP: 45258D105